Table 3.
Confocal data of the study population
| Baseline | Month 3 | Month 6 | Month 9 | Month 12 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Latanoprost | Tafluprost | Latanoprost | Tafluprost | Latanoprost | Tafluprost | Latanoprost | Tafluprost | Latanoprost | Tafluprost | |
| Epithelial density cells/mm2 mean ± SD (CI 95%) | 5800 ± 1136 (5393;6207) | 6370 ± 928 (6026;6714) | 6079 ± 677 (5833;6326) | 6244 ± 939 (5902;6585) | 6001 ± 610 (5782;6219) | 6286 ± 947 (5942;6631) | 5969 ± 677 (5738;6200) | 6085 ± 892 (5766;6404) | 5848 ± 726 (5592;6103) | 6051 ± 886 (5728;6373) |
| Fiber density per frame mean ± SD (CI 95%) | 4.7 ± 1.7 (4.1;5.2) | 4.1 ± 1.3 (3.7;4.5) | 4.8 ± 1.6 (4.3;5.4) | 4.3 ± 1.5 (3.8;4.9) | 4.1 ± 1.8 (3.5;4.7) | 4.8 ± 1.8 (4.1;5.4) | 4.4 ± 1.7 (3.8;5) | 4.1 ± 1.5 (3.6;4.7) | 4.8 ± 1.7 (4.2;5.4) | 4 ± 1.6 (3.5;4.5) |
| Density of dendritic cells per frame mean ± SD (CI 95%) | 7.5 ± 9.3 (4.3;10.8) | 5.9 ± 5.3 (4;7.8) | 6.7 ± 7.6 (4.1;9.3) | 5.4 ± 4.9 (3.7;7.2) | 9.2 ± 9.5 (5.9;12.4) | 8.7 ± 8.9 (5.5;11.9) | 8.3 ± 7 (5.9;10.6) | 7.3 ± 7.1 (4.7;10) | 9.3 ± 7.6 (6.7;12) | 7.2 ± 5.3 (5.4;9.1) |
| Endothelial density cells/mm2 mean ± SD (CI 95%) | 2987 ± 1276 (2398;3577) | 2743 ± 588 (2503;2984) | 2454 ± 652 (2144;2764) | 2692 ± 520 (2469;2914) | 2566 ± 724 (2157;2976) | 2632 ± 325 (2467;2796) | 2325 ± 610 (1980;2671) | 2477 ± 358 (2330;2623) | 2453 ± 307 (2263;2643) | 2566 ± 442 (2377;2756) |
| Sub-basal nerve reflectivity, (grade 0/1/2/3/4) | 2/2/8/20/3 | 0/0/14/13/5 | 0/1/9/19/6 | 1/3/8/16/4 | 0/4/9/16/6 | 0/0/11/18/3 | 0/2/6/17/10 | 0/2/10/14/6 | 0/3/9/16/7 | 0/3/12/11/6 |
| Sub-basal nerve tortuosity, (grade 0/1/2/3/4) | 1/1/11/17/5 | 0/1/10/10/11 | 0/6/11/7/11 | 0/4/9/9/10 | 0/2/12/10/11 | 0/1/9/15/7 | 1/3/8/16/7 | 1/5/6/14/6 | 0/1/9/17/8 | 0/3/7/10/12 |
| Sub-basal nerve beading, (yes/no) | 27/8 | 24/8 | 30/5 | 24/8 | 31/4 | 24/8 | 33/2 | 24/8* | 33/2 | 24/8* |
| Presence of activation of the anterior stromal keratocytes, (yes/no) | 10/25 | 16/16 | 21/14 | 21/11 | 24/11 | 26/6 | 26/9 | 26/6 | 28/7 | 27/5 |
| Branching pattern, (yes/no) | 30/5 | 27/5 | 30/5 | 27/5 | 30/5 | 27/5 | 32/3 | 27/5 | 35/0 | 27/5** |
Inter-treatment and intra-treatment ANOVA (mixed-effect models) not significant
ANOVA analysis of variance, CI confidence interval, SD standard deviation
* p = 0.05 (inter-treatment χ 2); ** p = 0.04 (inter-treatment χ 2)